TỔNG QUAN HỆ THỐNG VỀ HIỆU LỰC VÀ AN TOÀN CỦA THUỐC PHỐI HỢP LIỀU CỐ ĐỊNH DORZOLAMIDE+TIMOLOL TRONG ĐIỀU TRỊ TĂNG NHÃN ÁP VÀ GLÔCÔM GÓC MỞ

Abstract

Introduction: Glaucoma is one of the most prevalent and severe eye diseases that heavily affects public health. It is necessary to expand treatment options that ensure effectiveness and safety and increase patients' access to treatment. Objectives: To systematically review the efficacy and safety of the fixed-dose combination Dorzolamide/Timolol (DTFC) compared to Brinzolamide/Timolol (BTFC) in patients with glaucoma and open-angle glaucoma. Methods: A systematic review was conducted following Cochrane guidelines and the PRISMA 2020 checklist. Literature searches were performed in PubMed and Ovid Embase up to April 2024. Eligible randomized controlled trials (RCTs) were independently screened, extracted, and assessed for risk of bias using the Cochrane ROB2 tool. Results: Nine RCTs met the inclusion criteria. DTFC demonstrated comparable intraocular pressure (IOP)-lowering efficacy to BTFC, with no clinically significant differences. Both treatments were generally well tolerated, with most adverse events being mild and not requiring additional intervention Conclusion: DTFC is an effective and well-tolerated option for IOP control in patients with glaucoma and open-angle glaucoma, offering a viable alternative to BTFC in clinical practice.